| Symbol | RCKTW |
|---|---|
| Name | ROCKET PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 9 CEDARBROOK DRIVE,SUITE 7530, THE EMPIRE STATE BUILDING, CRANBURY, New Jersey, 08512, United States |
| Telephone | +1 609 659-8001 |
| Fax | — |
| — | |
| Website | https://www.rocketpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001281895 |
| Description | Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. Additional info from NASDAQ: |
2026-07-07 19:13
📋 Malik Fady Ibraham (Director) plans to sell 11K shares of ROCKET PHARMACEUTICALS, INC. (at $3.88 each, total $41K) Filed: Jul 07, 2026 | ID: 005144
Read more
2026-07-07 00:00
WONG RODERICK 🟢 acquired 106.8K shares (1 derivative) of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.35 Transaction Date: Jun 18, 2026 | Filing ID: 027681
Read more
2026-07-07 00:00
Fong Peter 🟢 acquired 87.7K shares (1 derivative) of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.35 Transaction Date: Jun 18, 2026 | Filing ID: 027680
Read more
2026-07-06 23:59
Dolsten Mikael 🟢 acquired 87.7K shares (1 derivative) of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.35 Transaction Date: Jun 18, 2026 | Filing ID: 027679
Read more
2026-07-06 23:59
Malik Fady Ibraham 🟢 acquired 87.7K shares (1 derivative) of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.35 Transaction Date: Jun 18, 2026 | Filing ID: 027678
Read more
2026-07-06 23:59
SOUTHWELL DAVID P 🟢 acquired 87.7K shares (1 derivative) of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.35 Transaction Date: Jun 18, 2026 | Filing ID: 027677
Read more
2026-07-06 23:59
BOESS CARSTEN 🟢 acquired 87.7K shares (1 derivative) of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.35 Transaction Date: Jun 18, 2026 | Filing ID: 027676
Read more
2026-06-30 21:16
(99% Neutral) ROCKET PHARMACEUTICALS, INC. (RCKT) Announces New Board Appointment
Read more
2026-06-12 11:10
(80% Positive) ROCKET PHARMACEUTICALS, INC. (RCKT) Provides Update on programs for severe leukocyte adhesion deficiency-I (LAD-I)
Read more
2026-06-12 11:00
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07137338 | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of … | Phase1 | Dilated Cardiomyopathy (DCM) | Recruiting | 2026-06-01 | 2029-06-01 | ClinicalTrials.gov |
| NCT07486752 | BAG3-DCM Natural History Study | — | Dilated Cardiomyopathy (DCM) | Not_Yet_Recruiting | 2026-05-01 | 2033-03-01 | ClinicalTrials.gov |
| NCT06422351 | Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Def… | Phase2 | Pyruvate Kinase Deficiency | Suspended | 2026-04-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT07509398 | FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorec… | Phase2 | Unresectable Colorectal Cancer | Not_Yet_Recruiting | 2026-04-01 | 2031-12-01 | ClinicalTrials.gov |
| NCT07333053 | Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Color… | Na | Unresectable Colorectal Cancer | Recruiting | 2026-03-31 | 2027-12-31 | ClinicalTrials.gov |
| NCT06644742 | PKP2-ACM Natural History Study | — | Cardiomyopathies | Recruiting | 2026-03-01 | 2031-04-01 | ClinicalTrials.gov |
| NCT07209787 | SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Mul… | Phase4 | Rectal Cancer | Recruiting | 2025-10-21 | 2027-08-31 | ClinicalTrials.gov |
| NCT07369830 | The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function | Na | Rectal Cancer | Recruiting | 2025-10-15 | 2029-06-30 | ClinicalTrials.gov |
| NCT06662643 | A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With… | Na | Rectal Cancer | Active_Not_Recruiting | 2024-05-08 | 2029-12-30 | ClinicalTrials.gov |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Local… | Phase2 | Locally Advanced Rectal Carcinoma | Recruiting | 2024-03-16 | 2026-12-01 | ClinicalTrials.gov |
| NCT06214507 | Danon Disease Natural History Study | — | Danon Disease | Recruiting | 2023-12-20 | 2030-03-01 | ClinicalTrials.gov |
| NCT06092034 | A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease | Phase2 | Danon Disease | Recruiting | 2023-09-05 | 2032-04-01 | ClinicalTrials.gov |
| NCT05885412 | A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Media… | Phase1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Recruiting | 2023-08-29 | 2029-09-01 | ClinicalTrials.gov |
| NCT05548855 | Natural History of Danon Disease | — | Danon Disease | Completed | 2022-09-26 | 2023-10-31 | ClinicalTrials.gov |
| NCT06282432 | Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I … | — | Leukocyte Adhesion Deficiency | Active_Not_Recruiting | 2022-03-09 | 2036-10-04 | ClinicalTrials.gov |
| NCT07527975 | Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Effic… | — | Fanconi Anemia | Enrolling_By_Invitation | 2022-02-01 | 2038-05-01 | ClinicalTrials.gov |
| NCT04967729 | COVID-19 and Lung Ultrasound Utility | Na | Covid19 | Completed | 2021-06-10 | 2022-06-06 | ClinicalTrials.gov |
| NCT04525352 | A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infant… | Phase1 | Infantile Malignant Osteopetrosis | Terminated | 2020-11-19 | 2021-05-21 | ClinicalTrials.gov |
| NCT04793607 | Interventions for Malignant Pleural Effusions Impact on Fatigue | — | Malignant Pleural Effusion | Unknown | 2020-09-01 | 2021-10-01 | ClinicalTrials.gov |
| NCT04248439 | Gene Therapy for Fanconi Anemia, Complementation Group A | Phase2 | Fanconi Anemia Complementation Group A | Active_Not_Recruiting | 2020-07-15 | 2026-05-05 | ClinicalTrials.gov |
| NCT04105166 | Gene Therapy for Pyruvate Kinase Deficiency (PKD) | Phase1 | Pyruvate Kinase Deficiency | Completed | 2020-07-06 | 2025-06-09 | ClinicalTrials.gov |
| NCT04437771 | Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex … | — | Fanconi Anemia Complementation Group A | Active_Not_Recruiting | 2020-06-01 | 2034-01-17 | ClinicalTrials.gov |
| NCT04069533 | Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Sub… | Phase2 | Fanconi Anemia Complementation Group A | Active_Not_Recruiting | 2019-11-28 | 2025-02-01 | ClinicalTrials.gov |
| NCT03812263 | A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects Wit… | Phase1 | Leukocyte Adhesion Defect - Type I | Completed | 2019-08-30 | 2023-09-12 | ClinicalTrials.gov |
| NCT03882437 | Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP… | Phase1 | Danon Disease | Unknown | 2019-04-17 | 2025-03-24 | ClinicalTrials.gov |
| NCT03825783 | A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects… | Phase1 | Leukocyte Adhesion Defect - Type I | Withdrawn | 2019-04-15 | 2021-10-01 | ClinicalTrials.gov |
| NCT03831386 | Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System | Na | Pleural Effusion | Recruiting | 2019-01-31 | 2026-12-31 | ClinicalTrials.gov |
| NCT06082414 | Systemic Management in Extremely Preterm and Extremely Low Birth Weight Infants | — | Bronchopulmonary Dysplasia | Completed | 2019-01-30 | 2020-01-29 | ClinicalTrials.gov |
| NCT03814408 | A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With F… | Phase1 | Fanconi Anemia Complementation Group A | Unknown | 2019-01-11 | 2022-03-01 | ClinicalTrials.gov |
| NCT03766386 | The Natural History of Danon Disease | — | Danon Disease | Unknown | 2018-11-30 | 2024-11-01 | ClinicalTrials.gov |
| NCT05727358 | Effectiveness of Group Acceptance and Commitment Therapy in Treating Acute Stro… | Na | Acute Stroke Patients With Depression | Completed | 2018-08-01 | 2021-08-31 | ClinicalTrials.gov |
| NCT03311165 | Epidemiological Study of Neonatal Acute Respiratory Distress Syndrome (ARDS) | — | Neonatal Acute Respiratory Distress Syndrome(ARDS) | Completed | 2018-01-01 | 2019-06-30 | ClinicalTrials.gov |
| NCT03319186 | EDIT Management Feasibility Trial | Na | Pleural Effusion, Malignant | Unknown | 2017-08-28 | 2018-11-01 | ClinicalTrials.gov |
| NCT02937974 | Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD | Phase4 | Pulmonary Disease, Chronic Obstructive | Unknown | 2016-10-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02805062 | Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients W… | — | Pleural Effusion, Malignant | Unknown | 2016-06-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT01331018 | Gene Therapy for Fanconi Anemia | Phase1 | Fanconi Anemia | Terminated | 2012-02-22 | 2024-02-15 | ClinicalTrials.gov |
Total clinical trials: 36
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Other | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| SIS-reinforced anastomosis | Other | Phase PHASE4 | Rectal Cancer | RECRUITING | NCT07209787 |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Other | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Other | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Other | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Other | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Other | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | Other | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| Magnetic Resonance Imaging | Other | Preclinical | Pleural Effusion, Malignant | UNKNOWN | NCT02805062 |
| Digital Pleural Manometry | Other | Preclinical | Pleural Effusion, Malignant | UNKNOWN | NCT02805062 |
| Placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | UNKNOWN | NCT02937974 |
| Xuebijing | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | UNKNOWN | NCT02937974 |
| Placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | UNKNOWN | NCT02937974 |
| Xuebijing | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | UNKNOWN | NCT02937974 |
| Chest drain and talc pleurodesis | Other | Approved | Pleural Effusion, Malignant | UNKNOWN | NCT03319186 |
| EDIT Management | Other | Approved | Pleural Effusion, Malignant | UNKNOWN | NCT03319186 |
| no intervention | Other | Preclinical | Neonatal Acute Respiratory Distress Syndrome(ARDS) | COMPLETED | NCT03311165 |
| no intervention | Other | Preclinical | Neonatal Acute Respiratory Distress Syndrome(ARDS) | COMPLETED | NCT03311165 |
| RP-L102 | Other | Phase PHASE1 | Fanconi Anemia Complementation Group A | UNKNOWN | NCT03814408 |
| Pleural procedures | Procedure | Preclinical | Malignant Pleural Effusion | UNKNOWN | NCT04793607 |
| RP-L201 | Other | Phase PHASE1 | Leukocyte Adhesion Defect - Type I | WITHDRAWN | NCT03825783 |
| RP-L401 | Other | Phase PHASE1 | Infantile Malignant Osteopetrosis | TERMINATED | NCT04525352 |
| Group-based Acceptance and Commitment Therapy | Drug | Approved | Acute Stroke Patients With Depression | COMPLETED | NCT05727358 |
| Group-based Acceptance and Commitment Therapy | Drug | Approved | Acute Stroke Patients With Depression | COMPLETED | NCT05727358 |
| RP-A501 | Other | Phase PHASE1 | Danon Disease | UNKNOWN | NCT03882437 |
| Device: Butterfly iQ | Device | Approved | Covid19 | COMPLETED | NCT04967729 |
| Device: Butterfly iQ | Device | Approved | Covid19 | COMPLETED | NCT04967729 |
| no interventions | Other | Preclinical | Bronchopulmonary Dysplasia | COMPLETED | NCT06082414 |
| no interventions | Other | Preclinical | Bronchopulmonary Dysplasia | COMPLETED | NCT06082414 |
| RP-L201 | Other | Phase PHASE1 | Leukocyte Adhesion Defect - Type I | COMPLETED | NCT03812263 |
| Cardiac Assistive Device | Device | Preclinical | Danon Disease | COMPLETED | NCT05548855 |
| Heart Transplant | Other | Preclinical | Danon Disease | COMPLETED | NCT05548855 |
| Prednisone | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Plerixafor | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Methylprednisolone | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Leukapheresis | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Genetically Engineered Hematopoietic Stem Progenitor Cells | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Filgrastim | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Bone Marrow Aspiration | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Prednisone | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Plerixafor | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Methylprednisolone | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Leukapheresis | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Genetically Engineered Hematopoietic Stem Progenitor Cells | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Filgrastim | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Bone Marrow Aspiration | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Prednisone | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Plerixafor | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Methylprednisolone | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Leukapheresis | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Genetically Engineered Hematopoietic Stem Progenitor Cells | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Filgrastim | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| Bone Marrow Aspiration | Other | Phase PHASE1 | Fanconi Anemia | TERMINATED | NCT01331018 |
| RP-L102 | Other | Phase PHASE2 | Fanconi Anemia Complementation Group A | ACTIVE_NOT_RECRUITING | NCT04069533 |
| Direct Anastomosis Plus Prophylactic Ileostomy | Other | Approved | Rectal Cancer | ACTIVE_NOT_RECRUITING | NCT06662643 |
| Delayed transanal pull-through anastomosis | Other | Approved | Rectal Cancer | ACTIVE_NOT_RECRUITING | NCT06662643 |
| Direct Anastomosis Plus Prophylactic Ileostomy | Other | Approved | Rectal Cancer | ACTIVE_NOT_RECRUITING | NCT06662643 |
| Delayed transanal pull-through anastomosis | Other | Approved | Rectal Cancer | ACTIVE_NOT_RECRUITING | NCT06662643 |
| RP-L301 | Other | Phase PHASE1 | Pyruvate Kinase Deficiency | COMPLETED | NCT04105166 |
| Gravity-Based IPC | Other | Approved | Pleural Effusion | RECRUITING | NCT03831386 |
| Vacuum-Based IPC | Other | Approved | Pleural Effusion | RECRUITING | NCT03831386 |
| Intravenous Chemotherapy（IVC） | Drug | Approved | Unresectable Colorectal Cancer | RECRUITING | NCT07333053 |
| Transarterial infusion chemotherapy (TAIC) | Drug | Approved | Unresectable Colorectal Cancer | RECRUITING | NCT07333053 |
| RP-A501 | Other | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| RP-L102 | Other | Phase PHASE2 | Fanconi Anemia Complementation Group A | ACTIVE_NOT_RECRUITING | NCT04248439 |
| Tislelizumab | Other | Phase PHASE2 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT06312982 |
| Tislelizumab | Other | Phase PHASE2 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT06312982 |
| Clostridium butyricum (live) Tablets(Meiya) | Other | Approved | Rectal Cancer | RECRUITING | NCT07369830 |
| Clostridium butyricum (live) Tablets(Meiya) | Other | Approved | Rectal Cancer | RECRUITING | NCT07369830 |
| Intravenous Chemotherapy（IVC） | Drug | Approved | Unresectable Colorectal Cancer | RECRUITING | NCT07333053 |
| Transarterial infusion chemotherapy (TAIC) | Drug | Approved | Unresectable Colorectal Cancer | RECRUITING | NCT07333053 |
| SIS-reinforced anastomosis | Other | Phase PHASE4 | Rectal Cancer | RECRUITING | NCT07209787 |
| SIS-reinforced anastomosis | Other | Phase PHASE4 | Rectal Cancer | RECRUITING | NCT07209787 |
| FMT Combined with Standard First-Line Therapy | Drug | Phase PHASE2 | Unresectable Colorectal Cancer | NOT_YET_RECRUITING | NCT07509398 |
| Standard First-Line Therapy | Drug | Phase PHASE2 | Unresectable Colorectal Cancer | NOT_YET_RECRUITING | NCT07509398 |
| FMT Combined with Standard First-Line Therapy | Drug | Phase PHASE2 | Unresectable Colorectal Cancer | NOT_YET_RECRUITING | NCT07509398 |
| Standard First-Line Therapy | Drug | Phase PHASE2 | Unresectable Colorectal Cancer | NOT_YET_RECRUITING | NCT07509398 |
| No intervention | Other | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| Safety and efficacy assessments | Other | Preclinical | Fanconi Anemia Complementation Group A | ACTIVE_NOT_RECRUITING | NCT04437771 |
| RP-L102 | Other | Preclinical | Fanconi Anemia | ENROLLING_BY_INVITATION | NCT07527975 |
| RP-L301 | Other | Phase PHASE2 | Pyruvate Kinase Deficiency | SUSPENDED | NCT06422351 |
| RP-A601 | Other | Phase PHASE1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | RECRUITING | NCT05885412 |
| RP-L301 | Other | Phase PHASE2 | Pyruvate Kinase Deficiency | SUSPENDED | NCT06422351 |
| RP-A601 | Other | Phase PHASE1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | RECRUITING | NCT05885412 |
| RP-A601 | Other | Phase PHASE1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | RECRUITING | NCT05885412 |
| RP-L301 | Other | Phase PHASE2 | Pyruvate Kinase Deficiency | SUSPENDED | NCT06422351 |
| RP-A601 | Other | Phase PHASE1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | RECRUITING | NCT05885412 |
| RP-L301 | Other | Phase PHASE2 | Pyruvate Kinase Deficiency | SUSPENDED | NCT06422351 |
| no intervention | OTHER | Preclinical | Neonatal Acute Respiratory Distress Syndrome(ARDS) | COMPLETED | NCT03311165 |
| SIS-reinforced anastomosis | DEVICE | Phase PHASE4 | Rectal Cancer | RECRUITING | NCT07209787 |
| RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) | GENETIC | Phase PHASE1 | Dilated Cardiomyopathy (DCM) | RECRUITING | NCT07137338 |
| No intervention | OTHER | Preclinical | Danon Disease | RECRUITING | NCT06214507 |
| RP-A601 | GENETIC | Phase PHASE1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | RECRUITING | NCT05885412 |
| Cardiac Assistive Device | DEVICE | Preclinical | Danon Disease | COMPLETED | NCT05548855 |
| Heart Transplant | PROCEDURE | Preclinical | Danon Disease | COMPLETED | NCT05548855 |
| RP-L401 | BIOLOGICAL | Phase PHASE1 | Infantile Malignant Osteopetrosis | TERMINATED | NCT04525352 |
| Safety and efficacy assessments | OTHER | Preclinical | Fanconi Anemia Complementation Group A | ENROLLING_BY_INVITATION | NCT04437771 |
| RP-L301 | BIOLOGICAL | Phase PHASE2 | Pyruvate Kinase Deficiency | NOT_YET_RECRUITING | NCT06422351 |
| RP-A501 | GENETIC | Phase PHASE2 | Danon Disease | RECRUITING | NCT06092034 |
| RP-L102 | BIOLOGICAL | Phase PHASE2 | Fanconi Anemia Complementation Group A | ACTIVE_NOT_RECRUITING | NCT04248439 |
| RP-L201 | BIOLOGICAL | Phase PHASE1 | Leukocyte Adhesion Defect - Type I | WITHDRAWN | NCT03825783 |
Total products: 132